



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets

(11)



EP 1 143 013 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
10.10.2001 Bulletin 2001/41

(51) Int Cl.7: C12Q 1/68, G01N 33/50  
// C12N5/10

(21) Application number: 00400923.9

(22) Date of filing: 03.04.2000

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU

MC NL PT SE

Designated Extension States:

AL LT LV MK RO SI

(71) Applicant: WARNER-LAMBERT COMPANY  
Morris Plains New Jersey 07950 (US)

(72) Inventors:

- Normant, Emmanuel  
92160 Antony (FR)

- Allen, Janet  
92190 Meudon (FR)
- Roman, François  
94400 Vitry sur Seine (FR)
- Brunelle, Gilles  
92160 Antony (FR)

(74) Representative: Becker, Philippe  
Cabinet Becker & Associés  
10, rue de Milan  
75009 Paris (FR)

## (54) Methods and compositions for screening IcraC modulators

(57) The present invention relates to compositions and methods directed at screening or characterizing compounds that modulate the activity of calcium channels in cells preferably, calcium-release activated channels in cells. The compositions and methods can be used to produce inhibitors or activators of said channel, which represent leads or candidate therapeutic drugs for treating various pathological conditions. More spe-

cifically, the method comprises (a) contacting a test compound and a calcium channel activator, preferably an IcraC activator with a population of calcium channel expressing cells, preferably IcraC expressing cells containing a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter, and (b) determining the activity of the test compound on the calcium release-activated channel by assessing the reporter gene expression in said cells.

BEST AVAILABLE COPY

EP 1 143 013 A1

**Description****Field of Invention**

- 5 [0001] The present invention relates generally to compositions and methods for screening compounds that modulate calcium entry or calcium-mediated activity within cells. More specifically, this invention discloses compositions and methods, including cell based assays, directed at screening or characterizing compounds that modulate the activity of calcium-release activated channels in cells. The compositions and methods can be used to produce inhibitors or activators of said channel, which represent leads or candidate therapeutic drugs for treating various pathological conditions.
- 10

**Background of the invention**

- [0002] Calcium influx and regulation play a critical role in many cellular processes in both excitable and non-excitable mammalian cells, including exocytosis, gene expression, cell differentiation, cell activation, contraction, etc. In non-excitable cells, such as immune cells, calcium concentration and flux are regulated essentially by voltage-independent  $\text{Ca}^{++}$  channels (sometimes referred to as capacitative calcium entry (CCE)), designated store-operated channels (SOC) or receptor-operated channels (ROC). The activity of these channels is essential in the regulation of calcium entry and participates directly in many important cellular processes such as cell activation or maturation for instance. A particularly important type of store-operated calcium channel is the Calcium release-activated channel (I<sub>Crac</sub>), which is opened in response to depletion of intracellular calcium stores and mediates various intracellular transduction signals.
- 15 [0003] For instance, the I<sub>Crac</sub> channel is involved in T cell activation following binding of an antigen to the T Cell Receptor (TCR). The full activation of T lymphocytes is due to the stimulation of the TCR/CD3 complex and CD2, CD4 or CD28 (see for review (1)). Upon antigenic stimulation of T-cells, (2) nuclear factor of activated T cells (NFAT) is required for the production of immunoregulatory molecules such as interleukins, IFN- $\gamma$ , or TNF- $\alpha$  (3). NFAT is a complex including a constitutive cytoplasmic component expressed in resting immunomodulatory cells such as T and B-cells, which translocate to the nucleus, and an inducible nuclear component consisting of dimers of fos- and jun-family proteins. Dephosphorylation of the cytoplasmic component of NFAT by  $\text{Ca}^{++}$ /calmodulin-dependent serine/threonine phosphatase, calcineurin, induces its translocation to the nucleus (4). Prolonged elevation of  $[\text{Ca}^{++}]$  level, beyond the initial transient increase resulting from the emptying of calcium intracellular pools, is required to maintain calcineurin phosphatase in activated state. After stimulation of immunomodulatory cells such as T-cell by external components, this calcium mobilization is the outcome of capacitative calcium entry, a process originated by the depletion of  $\text{Ca}^{++}$  store and the inflow of extracellular calcium through the specific Calcium release-activated  $\text{Ca}^{++}$  channel (I<sub>Crac</sub>) (5, 6). Capacitative  $\text{Ca}^{++}$  entry is triggered by stimulation of various receptors such as T-CR, B-CR, high affinity IgE receptor (Fc $\epsilon$ RI) and IgG receptor (Fc $\gamma$  RI) (via PLC $\gamma$ , and IP $_3$  receptor activation), CD40 (3) or by calcium ionophore (6, 7). Inhibitors of endoplasmic reticulum  $\text{Ca}^{++}$ /ATPase pump (thapsigargin (TG) (Thastrup et al., PNAS 87 (1990) 2466, ref (9)) or cyclopiazonic acid (CPA) (8)) directly deplete intracellular calcium stores and lead to I<sub>Crac</sub> activation. It has also been shown that I<sub>Crac</sub> is expressed by other blood cells such as T cells. Because of its role in interleukin production, I<sub>Crac</sub> is seen as a very interesting target for novel anti-inflammatory and immunosuppressing drugs or lead compounds. Furthermore, it has recently become clear that an I<sub>Crac</sub> like current is also present in endothelial cells (Am. J. Physiol. 269 (1995) C733, ref (10)) and in epithelial cells (J. Biol. Chem. 270 (1995) 169, ref (12)). Since radical damage could be linked to  $\text{Ca}^{++}$  inflow in these cells, it is thought that I<sub>Crac</sub> blockers would have a positive effect. In addition, since  $\text{Ca}^{++}$  inflow blockade leads to the IL2 synthesis blockade, I<sub>Crac</sub> blockers are potentially useful in proliferative or progressive diseases such as malignant tumors.
- 20
- 25
- 30
- 35
- 40
- 45
- 50

**Summary of the Invention**

- [0004] The present invention provides compositions and methods that allow an efficient screening for I<sub>Crac</sub> modulators. The invention discloses cell based assays allowing selective and efficient determination of the effect of any test compound on I<sub>Crac</sub> activity. The methods of this invention can be used to screen large amounts of test compounds, including libraries of compounds, on a high throughput basis, by reducing the number of false positives, providing increased selectivity and easy monitoring of the effect of any compound. I<sub>Crac</sub> modulators represent high potential leads or candidate drugs for the treatment or alleviation of various pathological conditions, including immune-related
- 55

diseases such as auto-immune diseases, inflammation, allergy, asthma, cancers or other cell proliferative disorders.

[0005] In accordance with the present invention, a method is provided for screening a compound that modulates calcium channel activity, preferably calcium release-activated channel (I<sub>Crac</sub>) activity, comprising:

- 5      a. contacting a test compound and a selective calcium channel activator, preferably an I<sub>Crac</sub> activator with a population of calcium channel expressing cells, preferably I<sub>Crac</sub> expressing cells, said cells further containing a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter, and
- b. determining the activity of the test compound on the calcium release-activated channel by assessing the expression of the reporter gene in said cells.

10

[0006] In a particular embodiment, the determination of the reporter gene expression comprises:

- 15      (i) contacting the cells of a) with a substrate of the reporter gene expression product, and
- (ii) determining the activity of the test compound on the calcium release-activated channel by assessing the hydrolysis of the substrate in said cells.

[0007] The reporter gene expression (e.g., hydrolysis of the substrate) can be correlated directly to the activity of the test compound: elevated expression levels (e.g. elevated levels of hydrolysis product) or an increase in expression levels (or the hydrolysis product) as compared to a control situation in the absence of the test compound indicates that the compound stimulates I<sub>Crac</sub>; low expression levels (e.g., low levels of hydrolysis product) or a decrease in the expression levels (or the hydrolysis product) as compared to a control situation in the absence of the test compound indicates that the compound inhibits I<sub>Crac</sub>.

[0008] Within a preferred embodiment, the cells are contacted with a selective I<sub>Crac</sub> activator, that preferentially does not activate Protein Kinase C ("PKC"). More preferably the selective I<sub>Crac</sub> inhibitor does not contain phorbol ester myristate acetate (PMA).

[0009] According to a preferred embodiment, the reporter gene is a β-lactamase gene and the substrate is a substrate of β-lactamase.

[0010] According to other preferred embodiments, the substrate is a ratiometric substrate, and/or the population of I<sub>Crac</sub>-expressing cells comprises a culture of blood cells, particularly lymphocytes or mastocytes.

[0011] In a particular variant of the present invention, the method further comprises the screening of the active test compounds detected in step b) above to determine which of these compounds modulate the expression activity of the reporter gene product (e.g., β-lactamase) in a non-NFAT dependent manner. This secondary screen allows to increase the selectivity of the method, by eliminating various test compounds which would modulate β-lactamase activity or, more generally, cell metabolism without specifically modulating I<sub>Crac</sub> (e.g., cytotoxic compounds, compounds that alter DNA or protein synthesis in the cells, etc.).

[0012] In order to discard as many as possible I<sub>Crac</sub>-unrelated hits, another secondary assay may be performed, in addition to or in replacement of the above-mentioned secondary assay. This assay uses a stable cell line where a NFAT-driven gene reporter expression is triggered by activation of a Gq-coupled receptor such as the muscarinic receptor 2 (M2). In this case, the only difference in the activation pathway is the trigger itself (I<sub>Crac</sub> or M2) but the whole downstream process stays identical.

[0013] The present invention can be used to screen various test compounds, including libraries of compounds (e.g., combinatorial libraries), either sequentially or in parallel, and to identify I<sub>Crac</sub> blockers or stimulators. The invention is also applicable to the further characterization or optimisation of I<sub>Crac</sub> modulators.

[0014] Other aspects of the present invention reside in kits for use in performing the above methods, cell cultures, supports and other reagents, as well as the use of said I<sub>Crac</sub> modulators for pharmaceutical purposes.

#### Detailed description of the invention

[0015] As indicated above, the present invention provides compositions and methods to analyse the activity of the I<sub>Crac</sub> channel and to screen for compounds that modulate said activity. The present invention describes compositions and methods allowing specific detection of I<sub>Crac</sub> activation via a reporter gene system. The present invention is suitable for high throughput screening of large amounts of compounds, and allows the identification of compounds with higher selectivity for calcium channels than was possible with previous strategies. As will be discussed below, the present methods and compositions provide significant advantages and broad spectrum of applications.

[0016] Calcium channels aid in the transportation of calcium through the plasma membrane and regulate the flux of calcium between the cell and its environment. Calcium channels can be characterised by their kinetic profile and their cell type physiology and pathology.

[0017] The invention is more specifically based on the use of a reporter system to measure the activity of I<sub>Crac</sub>. More

particularly, the invention uses a reporter system that monitors the Icrac-induced, NFAT-dependent production of a reporter gene product within cells. As indicated above, NFAT ("Nuclear factor of activated T cells") is produced and activated within T cells in response to Icrac stimulation. NFAT is a molecular complex including a constitutive cytoplasmic component expressed in resting T-cells and an inducible nuclear component consisting of dimers of fos- and jun-family proteins. Upon Icrac stimulation and Icrac-mediated calcium influx, the NFAT<sub>c</sub> translocates to the nucleus, where it specifically binds particular DNA regions (NFAT responsive or inducible promoter regions) and mediates gene expression. NFAT thus represents an interesting marker of Icrac activity within the cells, in particular within the cells of the immune system.

[0017] However, NFAT production/translocation may also result from or be influenced by other signalling pathways in the cells, including the Protein Kinase C (PKC) pathway for instance. In particular, many secondary pathway components are well known to interact with the activation of the NFAT promoter and, as a consequence, with the readout of the assay (see Figure 1). Among them, one can cite the AP-1 activators (e.g. PLC $\gamma$ / PKC pathways) or the calcineurin independent NFAT dephosphorylation pathway (CD28/PI3Kinase pathway).

[0018] The invention now proposes to screen Icrac activity by monitoring the Icrac-induced NFAT specific production of reporter molecules within the cell. The invention more specifically provides a novel cellular reporter assay that allows to specifically monitor the Icrac activity in a reliable manner.

[0019] A first object of this invention resides more specifically in a method for screening a compound that modulates calcium channel activity, preferably calcium release-activated channel (Icrac) activity, comprising:

- 20      a. contacting a test compound and a selective calcium channel activator, preferably an Icrac activator with a population of calcium channel expressing cells, preferably Icrac expressing cells, said cells further containing a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter, and
- b. determining the activity of the test compound on the calcium release-activated channel by measuring the reporter gene expression.

[0020] In a preferred embodiment, the Icrac activator (direct or indirect) in step a) is a selective Icrac activator, e.g., any product, treatment or condition allowing selective depletion of internal calcium stores. More preferably, the selective activator does not contain any co-stimulator of alternative signalling pathways such as PKC, to ensure higher selectivity of the method.

[0021] In another preferred embodiment, the method further comprises the screening of compounds that modulate reporter gene expression in a non-NFAT dependent manner or through a different activation pathway.

[0022] Each step and/or element of the method will now be described in more details.

#### The cell population

[0023] The invention comprises contacting various compounds and reagents with a population of calcium channel expressing cells, preferably Icrac-expressing cells that contain a particular reporter construct.

[0024] The cell population to be used in the invention preferably comprises mammalian Icrac-expressing cells, such as blood cells, epithelial cells or endothelial cells. Preferred cell populations comprise blood cells, such as lymphocytes (in particular T and B lymphocytes), mastocytes or dendritic cells, for instance. The cells are preferably established as cell lines, that can be cultured and stored. The cells can be of various mammalian origin, including human, rodent, bovine, porcine, canine, etc. Preferred cells are of human or rodent (e.g., murine, rat) origin. Typical examples of such cells include the Jurkat T cell line and the P815 mastocyte cell line. It should be understood that any other Icrac-expressing cell may be used in this invention.

[0025] In this regard, an object of this invention resides in a culture of mastocytes (or mastocyte-derived cells) that contain a reporter construct as described below. More specifically, the invention concerns any mastocyte-derived cell line, such as the P815 cell line, comprising a reporter construct as described below.

[0026] The invention also relates to any population of rodent immune cells, in particular any population of murine or rat immune cells, that comprises a reporter construct as described below. The invention describes the production of such cells, and demonstrates that they can be used to screen Icrac-mediated NFAT-dependent  $\beta$ -lactamase production with efficacy, sensitivity and reproducibility.

[0027] For performing the instant invention, it is not necessary that pure cell populations be used. In particular, the cell population may comprise 20% of non Icrac-expressing cells or of cells that do not contain the reporter construct. However, it is preferred to use cell populations that are preferably composed essentially of cells expressing the Icrac channel and containing the reporter system in order to increase the efficacy and sensitivity of the method.

[0028] The reporter construct contained in the cells comprises a reporter gene under the control of a NFAT-inducible promoter. The construct can be incorporated in a plasmid, vector, virus, episome, YAC, etc., i.e., in any appropriate genetic system that allows maintenance of the construct within the cells. Typical reporter constructs of this invention

comprise a plasmid, such as pcDNAIII, pUC, etc. in which at least one copy of the reporter gene and promoter has been inserted. The plasmid may further comprise a marker gene, allowing selection of the recombinant cells that contain the reporter construct. Alternatively, the reporter construct may be integrated into the genome of the cells, by any conventional technique, including recombination, transposons, viral integration etc. In preferred embodiments, the reporter construct is stably introduced into the cells using an extrachromosomal vector. More preferably, the construct is stable so that it remains present in the cells after several (preferably 100) cell divisions under selection pressure.

5 [0029] The reporter gene can be any nucleic acid encoding a product whose presence in a cell can be determined. The reporter gene may be any cDNA encoding a polypeptide whose presence in a cell can be visualized or determined easily. Examples of such reporter genes include any nucleic acid encoding a polypeptide such as green fluorescent 10 protein (and variants of)  $\beta$ -galactosidase, alkaline phosphatase, luciferase,  $\beta$ -lactamase, or derivatives or homologs thereof.

[0030] In a preferred embodiment, the reporter gene is a  $\beta$ -lactamase gene.

15 [0031] The  $\beta$ -lactamase gene may be any nucleic acid molecule encoding a  $\beta$ -lactamase polypeptide, i.e., a polypeptide that can hydrolyse a  $\beta$ -lactam ring. A preferred  $\beta$ -lactamase gene is the bacterial gene as described in Zlokarnik et al (13). It should be understood that any variant, fragment, or analog thereof can be used without deviating from the instant invention.

20 [0032] The NFAT-inducible promoter can be any transcriptional promoter comprising a NFAT-responsive region, i.e., a promoter that is activated in the presence of NFAT and essentially inactive in the absence of NFAT. The promoter can be any promoter functional in mammalian cells, comprising one or several copies of a NFAT binding domain. More preferably, the promoter comprises one or several (e.g. 2-8) copies of the following sequence: GGAGGAAAAACT-GTTTCATACAGAAGGGGT (SEQ ID NO:1) or any derivative or variant thereof. Derivatives include fragments, as well as mutated, modified or deleted sequences, which can be produced by conventional methods known to the skilled artisan. The capacity of said variants/derivatives to confer NFAT-responsiveness to a promoter may be verified by conventional expression technique. A particular promoter to be used in the reporter construct comprises 3 repeats of 25 SEQ ID NO:1. The sequence of a typical NFAT-inducible promoter is described in Mattila et al (19).

30 [0033] The reporter construct (or any vector containing the same) may be introduced into the cells by conventional techniques, including electroporation, calcium-phosphate precipitation, cationic lipids-, polymer- or liposome-mediated transfection, viral-mediated infection, etc. The cells used in the invention may comprise one or several copies of the reporter construct, preferably between 1 and 10 copies. The cells can be maintained in any culture medium suitable for mammalian cells, including RPMI, DMEM, generally around 37°C (for human cells), supplemented with conventional additives (antibiotics, amino acids, serum, etc.). Preferred medium comprise elevated Calcium concentration (e.g., above about 1mM), such as DMEM. The cells can be cultured and/or stored in any appropriate device (tubes, flasks, bottles, etc.). Cell viability and/or absence of contamination can be verified prior to carrying out the methods of this invention.

### 35 The cellular assays

#### Primary screen

40 [0034] The method of this invention comprises contacting a test compound with the cell population under particular conditions and measuring the reporter gene expression in the cells, as an indication of the effect of the test compound. Typically, the effect of the test compound is compared to the level of expression as measured in the absence of any test compound.

#### 45 Contacting test compound and activator with Icrcac expressing cells

50 [0035] Step a) of the method of this invention more specifically comprises contacting a test compound and an Icrcac activator with a population of Icrcac expressing cells which contain a reporter construct, as defined above. In a typical embodiment, the method comprises contacting several test compounds, in parallel, in particular at least two test compounds, more preferably at least 10, even more preferably at least 50 compounds. As will be discussed below, the invention is suited for High Throughput Screening of compounds and complete combinatorial libraries can be assayed, i.e., up to thousands of compounds.

#### The test compound

55 [0036] The test compound can be any product in isolated form or in mixture with any other material (e.g., any other product(s)). The compound may be defined in terms of structure and or composition, or it may be undefined. For instance, the compound may be an isolated and structurally-defined product, an isolated product of unknown structure,

a mixture of several known and characterized products or an undefined composition comprising one or several products. Examples of such undefined compositions include for instance tissue samples, biological fluids, cell supernatants, vegetal preparations, etc. The test compound may be any organic or inorganic product, including a polypeptide (or a protein or peptide), a nucleic acid, a lipid, a polysaccharide, a chemical product, or any mixture or derivatives thereof.

5 The compounds may be of natural origin, synthetic origin, including libraries of compounds.

[0037] As will be further discussed below, the present invention is particularly adapted for the screening of large numbers of compounds, such as combinatorial libraries of compounds. Indeed, the instant invention provides compositions and methods allowing efficient and simple screening of several compounds in short periods of time. In particular, the instant methods can be partially automated, thereby allowing efficient and simultaneous screening of large sets of

10 compounds.

[0038] Generally, the activity of the test compound(s) is unknown, and the method of this invention is used to identify compounds exhibiting the selected property (e.g, Icrc activators). However, in particular instances where the activity (or type of activity) of the test compound(s) is known or expected, the method can be used to further characterize said activity (in terms of specificity, efficacy, etc.) and/or to optimise said activity, by assaying derivatives of said test com-

15 pounds.

[0039] Preferably, the test compound(s) is (are) contacted with the cells in the presence of an Icrc activator. Indeed, the modulatory effect of the test compound(s) can be assessed preferentially where the Icrc channel is in activated status. To that effect, the cells are contacted with an Icrc activator, either before being contacted with the compound (s), or after or simultaneously. In a typical embodiment, each compound and activator is contacted simultaneously with

20 the cells.

#### Icrc activator

[0040] As explained above, an advantageous aspect of this invention resides in the targeted monitoring of Icrc activity, more preferably the selective Icrc-mediated activation of NFAT. To that effect, the nature of the Icrc activator (or activation medium or treatment) used in the assay is important, and a preferred and advantageous feature of the methods of this invention resides in the use of selective Icrc activators, which allow a screening for selective Icrc modulators (i.e., blockers or stimulators).

[0041] In this regard, the Icrc activator is preferably a calcium-release activator, i.e., a product that promotes depletion of intracellular calcium stores. Indeed, Icrc activation depends on depletion of intracellular calcium stores. In a preferred embodiment, the Icrc activator is a product or treatment or condition that selectively depletes intracellular calcium stores. In a specific embodiment, the Icrc activator (or activating treatment or medium) does not induce any costimulation of Protein Kinase C (PKC), in particular the activator does not comprise any stimulator of PKC such as phorbol ester myristate acetate (MPA).

[0042] Specific examples of Icrc activators for use in the invention include thapsigargin, cyclopiazonic acid, 2,5-di-(tert-butyl)-1,4-hydroquinone (Mason, M.J. et al., J.Biol.Chem. 266, 20856-20862, ref (17)), CD8 antibodies and phytohemagglutinin. A preferred Icrc activator to be used in this invention is thapsigargin (Thastrup et al., 1990 *supra*). Preferably, thapsigargin is used at a concentration ranging between 0.5 and 5  $\mu$ M, more preferably below 2 $\mu$ M.

[0043] In a specific embodiment, the cells are treated in step a) with thapsigargin in the absence of any costimulation of PKC, such as phorbol ester. More preferably, the cells are treated in step a) with thapsigargin alone. According to this embodiment, an Icrc-specific stimulus is used (i.e., thapsigargin) and the PKC pathway is not activated. This particular activation strategy allows to screen more selectively for Icrc activity.

[0044] The inventors have discovered that a more optimised signal to noise ratio can be obtained by increasing the calcium concentration in the medium. In particular, when calcium concentrations above 1 mM, preferably between 1 and 3 mM are used, the signal to noise ratio is raised by about 5-fold. Under these conditions, it is possible to screen, on a high throughput basis, with reliable and reproducible results, Icrc blockers in the absence of PKC co-stimulation. More preferred conditions comprise the incubation of the cells in a medium comprising between 1mM and 2mM calcium and devoid of phorbol ester.

[0045] These conditions represent a preferred embodiment of this invention. In this respect, a particular object of the present invention resides in a method of screening for Icrc blockers, comprising:

- a) contacting a test compound and an Icrc activator with a population of Icrc-expressing cells, said cells further containing a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter, said cells being cultivated in a medium containing at least 1mM calcium and lacking phorbol ester, and
- 55 b) determining the activity of the test compound on the calcium release-activated channel by measuring the reporter gene expression in said cells.

[0046] In another specific embodiment of this invention, the cells are contacted with the test compound(s) in the

absence of any Icrac activator. This embodiment allows to screen for Icrac activators.

[0047] The contacting can be performed in any appropriate support or device, including plate, tube, flask, and the like. Generally, contacting is performed in multi-well plates, allowing multiple assays to be carried out in parallel. Typical supports include microtiter plates, especially the 96-well or 384-well and higher throughput microtiter plate formats, which are easy to manage and easy to illuminate with conventional excitation. Other formats may also be used, including larger microtiter plates or nanotechnologies.

[0048] Depending on the support and test compound, varying amounts of cells can be used in the assay. Typically, between  $10^3$  and  $10^6$  cells are contacted with a compound, more preferably between  $10^4$  and  $10^5$  cells. As an illustration, in a 96-well microtiter plate, about  $10^5$  cells can be incubated in each well and contacted with a compound. In a 384-well microtiter plate, generally less than  $10^5$  cells, typically between 1-4  $10^4$  cells are incubated in each well and contacted with a compound (c.f. Fig. 7).

[0049] The amount (or concentration) of test compound can be adjusted by the user, depending on the type of compound (its toxicity, cell penetration capacity, etc.), the number of cells, the length of incubation period, etc. If necessary, the compound can be contacted in the presence of an agent that facilitates penetration or contact with the cells.

[0050] The contacting in step a) can last for about 2 to 6 hours, typically between 3 and 5 hours. Indeed, the cells and various reagents are preferably incubated for a period of time sufficient to allow de novo synthesis of the reporter gene expression product (e.g.,  $\beta$ -lactamase). Depending on the type of cells used, this period usually lasts about 3-4 hours. In a typical experiment, the cells and the above reagents are incubated for about 4 hours.

[0051] Step b) of the method comprises measuring the reporter gene expression, as an indication of the activity of the test compound.

The measuring can be performed according to various techniques, depending on the type of reporter gene being used. For instance, measuring can comprise dosing optical density or fluorescence emitted, where  $\beta$ -galactosidase or luciferase are used.

[0052] In a preferred embodiment, reporter gene expression is measured by assessing the hydrolysis level of a substrate of the reporter gene expression product. This embodiment is suitable for measuring expression of  $\beta$ -lactamase.

[0053] Accordingly, in a preferred embodiment, the method comprises

- a. contacting a test compound and a selective Icrac activator with a population of Icrac expressing cells, said cells further containing a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter,
- b. contacting the cells of a) with a substrate of the reporter gene expression product, and
- c. determining the activity of the test compound on the calcium release-activated channel by assessing the hydrolysis of the substrate in said cells.

[0054] In a more preferred embodiment, the reporter gene is  $\beta$ -lactamase and step b) of the current method comprises contacting the cells of a) with a substrate of  $\beta$ -lactamase.

[0055] In this regard, various substrates can be used to monitor  $\beta$ -lactamase expression, e.g., any product that contains a  $\beta$ -lactam ring and whose hydrolysis can be monitored. Preferred substrates are specific for  $\beta$ -lactamase (i.e., are essentially not hydrolysed in mammalian cells in the absence of  $\beta$ -lactamase), non toxic for mammalian cells, and/or their hydrolysis product can be monitored easily, for instance by fluorescence, radioactivity, enzymatic or any other detection method.

[0056] More preferred substrates are ratiometric substrates. Ratiometric substrates are substrates whose hydrolysis can be related directly to the reporter gene product activity regardless of the number of cells. A typical specific, non-toxic and ratiometric substrate for use in the instant invention is CCF2-AM (13). This substrate is conceived as a coumarin linked to a fluorescein molecule by a  $\beta$ -lactam ring. According to the fluorescence resonance energy transfer (FRET) principle, the coumarin (the donor) emits a blue light able to excite the fluorescein (acceptor) which, in turn, produces a green light. Accordingly, the uncleaved substrate emits green light and the product after  $\beta$ -lactamase hydrolysis emits a blue light. The ratio blue upon green fluorescence is directly related to the lactamase activity and not to the number of cells.

[0057] The concentration of the substrate can be adjusted by the skilled artisan, depending on the number of cells and Icrac activation conditions used, for instance. Usually, step b) lasts between 15' and 3 hours, preferably less than 2 hours. In a typical embodiment, the cells are contacted with the substrate during about 60 minutes. As a specific illustration, when CCF2-AM was used, an increase in the blue/green ratio could be detected during about two hours. However, a significant (and sufficient) signal could be detected 1 hour after loading the cells with the substrate.

[0058] Step c) of the method defined above comprises the determination of the activity of the test compound by assessing the hydrolysis of the substrate in said cells. Typically, the effect of the test compound is compared to the level of hydrolysis of the substrate as measured in the absence of any test compound or to a reference average value determined in the absence of any test compound.

- [0059] Measuring the hydrolysis comprises essentially a measure (or a determination of the relative quantity) of the hydrolysis product contained in each reaction sample. Said measure can be performed using various techniques known in the art, including fluorescence detection, radioactivity detection, colorimetric detection, enzymatic activity detection, antibody-antigen immune complex detection, etc. In a preferred embodiment, the hydrolysis product is detected and quantified using fluorescence detection. In this regard, various fluorochrome can be used and monitored on cell samples. In a typical experiment, where the CCF2-AM substrate is used, step c) comprises the excitation at about 405 nm and emission at 460 (cleaved substrate) and 535nm (uncleaved substrate), and the ratio 460/535 is estimated, which is directly correlated to the hydrolysis activity with the cells. It should be understood that any alternative detection method can be employed in the present method.
- [0060] As indicated above, one of the advantages of these methods is their capacity to screen large numbers of compounds in relatively short periods of time. For instance, in a typical experiment, about 90 compounds are tested in parallel on a 96-well plate and their activity is determined in about 5 hours. The method can be scaled-up to larger plates or device, allowing screening of thousands of compounds every day. Furthermore, the distribution of cells and all reagents in the reaction device can be automated, further increasing the yield and efficacy of the method.

**15 Secondary screen**

- [0061] In a particular variant of the present invention, the method comprises an additional screening of the compounds that modulate  $\beta$ -lactamase activity in a non-NFAT dependent manner. This secondary screen allows to increase the selectivity of the method, by eliminating various test compounds which would modulate  $\beta$ -lactamase activity or, more generally, cell metabolism, without specifically modulating Icrcac activity (e.g., cytotoxic compounds, compounds that alter DNA or protein synthesis in the cells, etc.). Accordingly, in a particular embodiment, the method of this invention further comprises d) the screening of the compounds obtained in c) in order to eliminate those which modulate  $\beta$ -lactamase activity in a non-NFAT dependent manner. More preferably, step d) comprises contacting the compounds selected in c) with a population of cells comprising a reporter construct comprising a  $\beta$ -lactamase gene under the control of a non-NFAT-inducible promoter, more preferably a CRE-inducible promoter.
- [0062] This secondary screen can be performed using various populations of cells, in particular mammalian cells, such as HEK cells for instance, or CHO, Jurkat, or Vero cells, for example. The reporter construct can be prepared in the same way as described above, except for the promoter region. In a specific embodiment, the promoter region comprises one or several (1 to 8, preferably 3) CRE sequences (CGTCA, SEQ ID NO:2), which are responsive to cyclic AMP concentration within cells. Other promoter regions can be used in this secondary assay, such as VIP responsive promoters, or promoters containing NFkB or JNK responsive element, for instance.
- [0063] Also, additional or alternative secondary screenings may be performed in order to further characterize or profile the selected compounds, including Ca-uptake, electrophysiology of the Icrcac channel etc.
- [0064] In this respect, in order to discard as many as possible Icrcac-unrelated hits, another secondary assay may be performed, in addition to or in replacement of the above-mentioned secondary assay. This assay uses a stable cell line where a NFAT-driven gene reporter expression is triggered by activation of a Gq-coupled receptor such as the muscarinic receptor 2 (M2). In this case, the only difference in the activation pathway is the trigger itself (Icrcac or M2) but the whole downstream process stays identical.
- [0065] The invention can be used to screen Icrcac modulators, with various therapeutic or research applications.
- [0066] In this regard, an Icrcac modulator can be defined as any compound that modulates the activity of Icrcac. A modulator can be a blocker or a stimulator, as defined below. Modulation of Icrcac activity can result from several mechanisms of action. In particular, Icrcac modulators can directly interact with Icrcac and modulate the Icrcac-mediated calcium inflow. As an example, the modulators can interact with Icrcac and prevent calcium entry within cells. Another type of modulators according to the present invention is a compound that modulates the activation of Icrcac, e.g., a compound that prevents or can modulate upstream activation of Icrcac. A further type of modulators according to the present invention comprises compounds that modulate the Icrcac-mediated signal transduction. Preferred modulators according to this invention are compounds that modulate Icrcac activation and/or that interact with Icrcac.
- [0067] Icrcac blockers designate more specifically any compound that blocks (or inhibits, or antagonizes) the activity of an Icrcac channel. More preferably, an Icrcac blocker is a compound that inhibits at least partially the Icrcac activity, typically by at least 20%, as compared to control situation in the absence of said compound. More preferred Icrcac blockers inhibit at least 40% of Icrcac activity, as measured by NFAT-mediated  $\beta$ -lactamase-dependent hydrolysis of a substrate.
- [0068] Icrcac stimulators designate more specifically any compound that stimulates (or increases, or facilitates) the activity of an Icrcac channel. More preferably, an Icrcac stimulator is a compound that causes an increase of at least 20% of Icrcac activity, as compared to control situation in the absence of said compound. More preferred Icrcac stimulators cause an increase of at least 40% of Icrcac activity, as measured by NFAT-mediated  $\beta$ -lactamase-dependent hydrolysis of a substrate.

[0069] The invention was validated using several molecules known to interact with NFAT activation pathways such as cyclosporin A (CsA) (14, 15), within Icrac expressing cells like T-cells (Jurkat) and mastocytes (16). Since DMSO is a commonly used vehicle for compound solubilization (as well as an anti-inflammatory molecule) its possible interaction with the NFAT-driven activation was also checked. We show here that this reagent, did not hinder the assay at a concentration of about 0.5%. The results presented in this application also illustrate the efficacy of the method since more than 3000 compounds have been screened very rapidly, leading to the identification of 3 efficient modulators of Icrac. Such Icrac modulators represent drug candidate or leads to be used in the treatment of various pathological conditions, including immune diseases (GVHD, auto-immune diseases, inflammation, allergies, asthma, etc.) and proliferative disorders (cancers, stenosis, etc.). The compounds may be used to treat, prevent, correct, alleviate or reduce the pathological condition, either alone or in combination with other pharmaceutically active molecules.

[0070] Other aspects and advantages of the present invention will be disclosed in the following experimental section, which should be regarded as illustrative and not limiting the scope of protection.

#### Abbreviations used:

[0071] TG: thapsigargin; CsA: cyclosporin, CPA: cyclopiazonic acid; PHA: phytohemagglutinin; PMA: phorbol myristate acetate; CHX: cycloheximide; Jk-NFAT-blac: jurkat cell line stably expressing  $\beta$ -lactamase under NFAT control; Jk-CMV-blac: jurkat cell line constitutively expressing  $\beta$ -lactamase; p815-NFAT-blac: p815 cell line expressing  $\beta$ -lactamase under NFAT control; HEK-CRE-blac: HEK cell line expressing  $\beta$ -lactamase under CRE control; NFAT: nuclear factor of activated T cells; CRE: cAMP Responsive Element; DMSO dimethyl sulfoxide.

#### Legend to the Figures

[0072] Fig.1. NFAT-related activation pathway.  
 [0073] Fig.2.

**A)** Principle of the gene-reporter cell-based assay.  $\beta$ -lactamase is expressed after activation of NFAT system which is triggered by  $[Ca^{++}]$  oscillations due to intracellular calcium pool depletion and Icrac stimulation. In this example the hydrolysis of  $\beta$ -lactamase substrate is used to determine the level of expression of  $\beta$ -lactamase.  
**B)** Effect of extracellular  $[Ca^{++}]$  on the reporter-protein ( $\beta$ -lactamase) synthesis as measured by hydrolysis of CCF2-AM. NFAT- $\beta$ -lactamase Jurkat cells were stimulated for 4hrs in RPMI medium (0.4 mM  $[Ca^{++}]$ ) or DME medium (1.8 mM  $[Ca^{++}]$ ) in presence of TG 1 $\mu$ M.  
**C)** Effect of TG concentration on  $\beta$ -lactamase synthesis. NFAT- $\beta$ -lactamase Jurkat cells were stimulated for 4hrs with various TG concentration in DME medium

[0074] Fig.3. NFAT-driven gene expression after TG 1 $\mu$ M stimulation in Jurkat and p815 cells. NFAT- $\beta$ -lactamase Jurkat cells and NFAT-blac p815 were incubated with various modulators for 4h, before substrate loading. 1) control; 2) TG 1 $\mu$ M + PMA 10nM; 3) TG 1 $\mu$ M; 4) CsA 10 nM; 5) CsA 100 nM; 6) DMSO 0.5%; 7) DMSO 1%; 8) DMSO 2%  
**[0075]** Fig.4. Effect of various inhibitors on TG-driven  $\beta$ -lactamase synthesis. NFAT- $\beta$ -lactamase Jurkat cells were incubated with various inhibitors/modulators together with TG 1 $\mu$ M for 4h, before substrate loading 1) control, 2) TG 1 $\mu$ M. TG 1 $\mu$ M was added with 3) CsA 50 nM, 4) okadaic acid , 5) calyculin, 6) Verapamil 10 $\mu$ M, 7) Diltiazem 10 $\mu$ M, 8) Nifedipine 10 $\mu$ M, 9) cycloheximide 10 $\mu$ g/ml, 10) DMSO 2%. 100% is defined as cells stimulated with TG 1 $\mu$ M alone.  
**[0076]** Fig.5. Effect of Cyclosporin on NFAT- $\beta$ -lactamase Jurkat cells stimulated by TG. NFAT- $\beta$ -lactamase Jurkat cells were treated with TG 1 $\mu$ M in presence of various concentration of Cyclosporin. 100% was defined as stimulated-cells without CsA.  
**[0077]** Fig.6. Effect of DMSO on various cell types and promoters. DMSO 3% were added to wells containing CMV- $\beta$ -lactamase Jurkat () and NFAT- $\beta$ -lactamase Jurkat () stimulated with TG 1  $\mu$ M, and CRE- $\beta$ -lactamase HEK cells stimulated with forskolin 10  $\mu$ M (). Results are expressed as the ratio of activities of each cell line without and with DMSO.

[0078] Fig.7. Stimulation of Jk-NFAT-blac in a 384 wells plate format.

#### Table 1

[0079] Relative potency of various activators of TG-driven  $\beta$ -lactamase synthesis in NFAT Jurkat cells.

#### Table 2

[0080] Effect of DMSO on loading capacity of and NFAT- $\beta$ -lactamase Jurkat cells.

**Examples****1. Materials and Methods****5 Cell-based assay**

[0081] *Cell line selection* Jurkat cell lines (Jk-NFAT- $\beta$ lac) stably transfected with plasmid containing 3xNFAT- $\beta$ -lactamase reporter gene (for NFAT promoter sequence see (19)), and plasmid containing CMV- $\beta$ -lactamase (Jk-CMV- $\beta$ lac), where CMV is a constitutively active promoter as well as HEK cells (HEK-CRE- $\beta$ lac) with 3xCRE- $\beta$ -lactamase (the CRE promoter contains CRE box sequence of CGTCA (20)) were obtained from Aurora Biosciences Corp (San Diego, CA).

The mastocyte monoclonal cell line (p815-NFAT- $\beta$ lac) stably transfected with plasmid containing 3xNFAT- $\beta$ -lactamase were obtained as follow. Cells ( $1.10^7$ /ml) were electroporated in a 0.4 cm gap cuvette using a BioRad Gene Pulser II at 960 $\mu$ F and 300V, using 20 $\mu$ g of pcDNAIII 3xNFAT- $\beta$ -lactamase Zeomycin expression vector (from Aurora Biosciences Corp; San Diego, CA) in DMEM medium. After 48h, electroporated p815 cells were selected for 2 weeks using 250 $\mu$ g/ml Zeocin (InVitrogen, CA). A pool of TG responding cells were first sorted, using FACS Vantage (Becton Dickinson, CA), and a week after, 200 cells were monosorted (one cell per well) from this pool. 15 clones grown up, and were tested as follow.

[0082] *Gene-reporter assay* Jurkat cells were grown in RPMI 1640 medium supplemented with 10% foetal bovine serum, 2mM L-glutamine, 1mM NEAA, 1mM Na pyruvate, 25mM HEPES, pH 7.4, gentamicin 100  $\mu$ g/ml. HEK-293 cells were grown in MEM glutamax, supplemented with 10% FBS, gentamycin 100 $\mu$ g/ml, HEPES 20 mM. Medium for stable cell propagation contained 250 $\mu$ g/ml Zeocin (Jk-NFAT- $\beta$ lac) or 800 $\mu$ g/ml Geneticin (Jk-CMV- $\beta$ lac, HEK-CRE- $\beta$ lac).

In a 96-well plate, 1  $\mu$ M Thapsigargin (TG) was used to stimulate NFAT Jurkat cells ( $10^5$  per well), for 4h at 37°C, 5%CO<sub>2</sub>, in Dulbecco's Modified Essential Medium ([Ca<sup>++</sup>] 1.8mM) 10% FBS, gentamycin 100 $\mu$ g/ml. Cells were then loaded, for 1 h in the dark at room temperature, with 12 $\mu$ M CCF2-AM (13). Fluorescence was monitored with a Fluostar (BMG, Germany) fluorimeter. Excitation was at 405 nm, and emission record at 460 nm and 535 nm. The ratio (460nm/535nm) of fluorescence unit (F.U.) was estimated after correction for background (medium without cells). HEK-CRE- $\beta$ lac were stimulated using Forskolin 10  $\mu$ M in the medium mentioned above ( $4 \times 10^4$  cells/well). All reagents were added with the stimulator agent (e.g. TG or forskolin), unless noticed.

[0083] *Optical measurement of Intracellular [Ca<sup>++</sup>].* Loading with 2 $\mu$ M fura-2-AM was performed with a  $3 \times 10^6$  cells suspension for 30 min at 37°C, in Hanks buffer saline solution (HBSS). Cells were washed and resuspended twice to minimize extracellular dye. Fura-2 fluorescence measurements were carried out in a water-jacketed cuvette (room temperature) with continuous stirring, containing 1 ml of the cells suspension. Fluorescence was monitored with a Shimadzu spectrofluorophotometer by continuously (1 sec intervals) collecting excitation signals at 340nm and 380nm and emission signal at 510nm. Maximal and minimal fluorescence were obtained by adding ionomycin 25 $\mu$ M and EGTA (20 mM) respectively and sequentially at the end of the experiment. The ratio of excitation signals at 340nm and 380nm was used to calculate [Ca<sup>++</sup>] as previously described (21) assuming a Kd of 155nM.

**40 Drugs**

[0084] Thapsigargin, phorbol ester myristate acetate (PMA), phytohemmagglutinin (PHA), okadaic acid, calyculin, cycloheximide, dry DMSO, cyclopiazonic acid, cyclosporin and Fura-2 were purchased from Sigma. CCF2-AM was from Aurora Biosciences. All cell culture reagents were from LifeTech (Gaithersburgh, MD). p815 cells were from ATCC (Manassas, VA. ATCC # TIB 64).

**2. NFAT activation in Jurkat cell lines.**

[0085] A gene reporter assay (see Fig.2A for schematic principle) was set up to study the T-cell activation and NFAT-driven gene production related to activation and gating of Icrac. In this test, co-stimulation with PKC activators was avoided, since the assay was made to identify Icrac blockers or inactivators but not PKC inhibitors. However, while thapsigargin alone can trigger a NFAT-related gene production, the resulting  $\beta$ -lactamase activity turned out to be weak in conventional conditions (conventional conditions being 0.4mM [Ca<sup>++</sup>]. (Fig. 2B). To overcome this problem and design a selective screening assay, we have found that when [Ca<sup>++</sup>]<sub>o</sub> was increased to 1.8 mM (instead of about 0.4 mM), the signal to noise ratio became 5-fold higher and suitable for an HTS assay. In addition, it was shown that the gene reporter ( $\beta$ -lactamase) expression was related to the TG concentration from 0 to 1  $\mu$ M; higher concentrations did not further increase the  $\beta$ -lactamase synthesis (Fig. 2C), and even a decrease was observed at concentrations of 5-10 $\mu$ M TG.

**3. Inhibitors and activators of NFAT system.**

[0086] Several known Icrac activators such as phytohemeagglutinin (PHA), thapsigargin (TG), cyclopiazonic acid (CPA) and antibody against CD28, were tested, and their relative potencies to stimulate  $\beta$ -lactamase expression checked. The results obtained (Table 1) show that TG is the most active Icrac activator, and, as previously described (22) the combination TG / PMA significantly increases the signal. Okadaic acid (OKA), a PP1A and PP2 phosphatase inhibitor blocked the  $\beta$ -lactamase synthesis, consistent with previous results (23) both on Jurkat cells (Fig. 4) and mastocytes (not shown). Calyculin, another phosphatase inhibitor, blocked the NFAT activation in a dose dependent manner (Fig. 4 and (11)). Cyclosporin (CsA), a calcineurin phosphatase inhibitor, suppressed the  $\beta$ -lactamase synthesis with an IC<sub>50</sub> at 17 nM (Fig. 5), in good agreement with previous report (18nM, see (22)). Jurkat cells are thought to lack voltage-dependent Ca<sup>++</sup>channels. In good agreement with this assumption, specific inhibitors of these channels (Verapamil, Diltiazem and Nifedipine) did not have any effect on the  $\beta$ -lactamase synthesis (Fig. 4) when used at 10 $\mu$ M. Toxic effects were detected at 50 $\mu$ M (weak loading, data not shown). Tazobactam, a  $\beta$ -lactamase inhibitor (Ki = 0.7 $\mu$ M) was shown to block both the NFAT-driven (Fig 4) and the constitutive  $\beta$ -lactamase (CMV-driven) with an IC<sub>50</sub> at 2 $\mu$ M.

**4. Effect of DMSO**

[0087] DMSO is a very common vehicle for water-insoluble compounds as well as a well-known anti-inflammatory compound. We tested the effect of this chemical on the different cell lines and different promoters described in this application. As shown in Figure 6, DMSO has no effect on Jk-CMV- $\beta$ lac cell  $\beta$ -lactamase (constitutive) synthesis. However, it did inhibit the Jk-NFAT- $\beta$ lac, p815-NFAT- $\beta$ lac and HEK-CRE- $\beta$ lac cells  $\beta$ -lactamase production, with an IC<sub>50</sub> at 1%. Furthermore, Table II indicated that the loading was not modified after DMSO treatment. To further study the DMSO inhibition mechanism, DMSO, CsA and CHX were added at different time after TG addition. The time course of the DMSO and CsA inhibitory effects are very much alike, and both compounds did not block  $\beta$ -lactamase synthesis if added 3hrs after TG activation, whereas the CHX time course pattern strongly diverged, exhibiting an inhibitory effect when added as long as 4hrs after TG stimulation, suggesting that the compound acted at the protein synthesis level. This DMSO inhibitory effect is equally detected with HEK-CRE- $\beta$ lac suggesting that DMSO acted after the [Ca<sup>++</sup>]<sub>i</sub> increase and before the protein synthesis. Confirming these results, [Ca<sup>++</sup>]<sub>i</sub> determination using Fura-2 as probe, showed that this compound had no effect on the Icrac channel itself.

**5. High Throughput Assay**

[0088] A test on a 3000 compounds sub-library was performed in the following conditions:

Plate preparation and cell stimulation

[0089] Seed cells at 10<sup>5</sup> cells / 180 $\mu$ l / well in DMEM medium (GIBCO Cat #) 90%, FBS 10% into 96-well clear bottom black plates (COSTAR cat # 3603). Add 18 $\mu$ l of thapsigargin (11.1  $\mu$ M) + 2 $\mu$ L of compound 1mM in 50% DMSO (i.e. 0.5% final DMSO). Incubate at 37°C, 5% CO<sub>2</sub> 90% humidity for 4h.

## Dye loading

[0090] 12 $\mu$ l of CCF2-AM 1mM were vigorously mixed with 60 $\mu$ l pluronic acid, and then with a 1ml PEG 400 solution. 40 $\mu$ l of the resulting solution was added to the wells. Plates were then wrapped into foil, gently agitated at room temperature from 45min to 2hrs.

## Fluorimeter assay

[0091] Excitation was performed at 405nm and emission at 460 and 535nm. The following controls were added in each plate. i) Blank, medium without cells; ii) positive control (100%), JkNFAT $\beta$ -lac stimulated with thapsigargin; iii) negative control (0%), non-stimulated JkNFAT $\beta$ -lac.

[0092] Ratio calculation was as follow. Mean of blank values was subtracted from the F.U.s (both for the F.U. 460nm and F.U. 535nm) and the ratio of resulting values (460/535) estimated. Usually, the negative control values were about 0.010 and the positive control's about 0.400-0.500.

## Secondary screening

[0093] To determine whether the selected hits have an effect either upstream or downstream the nuclear factor activation, their potential inhibition of CRE-driven  $\beta$ -lactamase synthesis is checked using HEK cells stably transformed with a CRE3x $\beta$ lactamase expression vector. The cells are stimulated for 6hrs with 10 $\mu$ M forskolin.

## Results

[0093] The assay showed that the intra and inter-plate standard deviation was not higher than 5% (data not shown). Out of the 3000 test compounds, 17 were screened as Icrac blockers in the assay, and 3 were selected after the secondary assay. This example shows that the method allows efficient, reliable and selective screening of Icrac modulators.

### 6. Discussion

[0094] In this application, a cell-based/gene reporter system is described. It allows convenient analysis of the NFAT activation process, since the amplitude of the inducible signal and the reproducibility of this assay is compatible with the use of 96-wells microtiter plate (preliminary data showed that 384-plate can be as well used with this assay Fig 7). Several modulators of the Icrac-related NFAT activation pathway were tested and their effects were found in good agreement with previous reports. Noteworthy, the NFAT-driven gene activation is likely to be a binary event, T-cells remain inactivated until activated (dephosphorylated) NFAT reaches a threshold concentration. The T-cell are then triggered to enter an activated state that is equivalent for all forms and concentration of stimuli (22, 24). In this context, IC<sub>50</sub>s reflected a decrease in the percentage in responder cells rather than in the intensity of the response in individual cells.

An important aspect of the test presented here, is the Icrac-specific stimulus used (i.e. TG) and the fact that PKC pathway was not activated here, leading to a more specific assay. Furthermore, to sort out bona fide Icrac modulators among non-specific compounds, another gene reporter assay involving a different response element (i.e. HEK-CRE-βlac based assay) has been set up, allowing to dramatically reduce the number of false positives. Other secondary low through put assay can be developed such as <sup>45</sup>Ca uptake and electrophysiology of the Icrac channel. The test is suitable for HTS. Indeed, cells have to receive a mixture of TG and the compound, be incubated at 37°C for 4h and loaded with CCF2-AM for 30min. An other asset of the technique is the β-lactamase substrate. CCF2 is non toxic, ratiometric and stay within cells for several hours. Then, β-lactamase appears to be the most suitable protein for gene reporter assay. Indeed, it can be monitored in living cells (unlike β-galactosidase or luciferase) and, since β-lactamase is a bacterial enzyme, no endogenous activity will cross react in mammalian cells (unlike alkaline phosphatase). But the most attracting feature of the test is that it allows the detection not only of bona fide Ca<sup>++</sup>-inflow blockers, but of molecules acting on Icrac activation level. Since it has been very recently proposed that this activation is the outcome of a scaffolding of several proteins (TRP, IP3 (26, 27) and SNAP25 (18)) any blocker of protein-protein interactions between these components is *de facto* a modulator of the Icrac activation. This could lead to the discovery of very specific molecules, with predictable low side effects, and not only to non-specific Ca<sup>++</sup> channel "corks".

During this study, DMSO was checked as a potential non specific β-lactamase blocker. We showed that DMSO blocked NFAT-driven β-lactamase expression both in mastocytes and lymphocytes as well as it blocked the CRE-driven β-lactamase expression in HEK cells with an IC<sub>50</sub> around 1%. Interestingly, we showed that DMSO inhibitory effect arose between NFAT activation and RNA translation, but did not act as a non-specific protein synthesis blocker. Further studies are needed to accurately spot the intracellular DMSO target. However, we showed that 0.5% DMSO did not hinder the assay and can be used as final concentration. Noteworthy, the pharmacological tools used in this study did not allow to detect differences (if any) between the Icrac channel from T-cells and mastocytes.

Accordingly, the cell based described here substantially facilitates screening procedures and broaden the investigation field aiming at the identification of novel reagents with therapeutic potential in inflammation-, cell proliferation (e.g., cancer)-, auto-immune- or allergy-related pathologies.

### 45 References

#### [0095]

1. Robey, E. and Allison, J. P. (1995) *Immunol. Today* **16**, 306-310.
2. Ghosh, P. et al. (1996). *J.Biol.Chem.* **271**, 7700-7704.
3. Rao, A., Luo, C., and Hogan, P. G. (1997) *Annu.Rev.Immunol.* **15**, 707-747.
4. Clipstone, N. A. and Crabtree, G. R. (1992) *Nature* **357**, 695-697.
5. Lewis, R. S. and Cahalan, M. D. (1990) *Annu.Rev.Physiol.* **52:415-30**, 415-430.

6. Berridge, M. J. (1995) *Biochem.J.* **312**, 1-11.
7. Fanger, C. M., et al. (1999) *J.Cell Biol.* **131**, 655-667.
- 5 8. Mason, M. J., et al. (5-11-1991) *J Biol Chem* **266**, 20856-20862.
9. Thastrup et al., PNAS 87 (1990) 2466
10. Am. J. Physiol. 269 (1995) C733
11. Li, W. and Handschumacher (1996) *Biochem.Biophys.Res.Commun.* **219**, 96-99.
12. J. Biol.Chem. 270 (1995) 169
- 15 13. Zlokarnik, et al. (1998) *Science* **279**, 84-88.
14. Flanagan, et al. (29-8-1991) *Nature* **352**, 803-807.
15. Loh, C et al. (3-5-1996) *J.Biol.Chem.* **271**, 10884-10891.
- 20 16. Hoth, M. and Penner, R. (1992) *Nature* **355**, 353-356.
17. Mason, M.J. et al., J.Biol.Chem. 266, 20856-20862
- 25 18. Yao, et al. (20-8-1999) *Cell* **98**, 475-485.
19. Mattila, et al. (1990) *EMBO J.* **9**, 4425-4433.
20. Yamagami, et al. (1988) *Ann N Y Acad Sci* **527**, 87-102.
- 30 21. Gryniewicz, et al. (1985) *J.Biol.Chem.* **260**, 3440-3450.
22. Negulescu, et al. (1994) *Proc.Natl.Acad.Sci. U.S.A.* **91**, 2873-2877.
- 35 23. Thevenin, C et al. (25-5-1991) *J.Biol.Chem.* **266**, 9363-9366.
24. Karttunen, J. and Shastri, N. (1991) *Proc Natl Acad Sci U S A* **88**, 3972-3976.
26. Boulay, et al. (2000) *Proc.Natl.Acad.Sci. USA* **96**, 14955-14960.
- 40 27. Putney, J. W. Jr. (2000) *Proc.Natl.Acad.Sci.USA* **96**, 14672-14674.

Table 1

| 45 | Icrac activator             | Ratio (460 nm / 535 nm) | % total (TG 1 μM) |
|----|-----------------------------|-------------------------|-------------------|
|    | TG 1μM                      | 0.688 ± 0.035           | 100               |
|    | PMA 10 nM                   | 0.012 ± 0.008           | 2                 |
| 50 | TG 1μM + PMA 10 nM          | 1.648 ± 0.119           | 240               |
|    | CPA 10 μM                   | 0.407 ± 0.041           | 59                |
|    | CPA 10 μM + PMA 10 nM       | 1.249 ± 0.032           | 182               |
|    | PHA 1μg/ml                  | 0.280 ± 0.116           | 41                |
|    | PHA 10μg/ml                 | 0.578 ± 0.040           | 84                |
| 55 | mAbCD28 30 ng/ml + PMA 10nM | 0.020 ± 0.010           | 4                 |
|    | mAbCD28 100 ng/ml + PMA10nM | 0.089 ± 0.023           | 13                |
|    | mAbCD28 300 ng/ml + PMA10nM | 0.254 ± 0.054           | 37                |
|    | mAbCD28 1000 ng/ml +        | 0.275 ± 0.032           | 40                |

Table 1 (continued)

| Icrac activator | Ratio (460 nm / 535 nm) | % total (TG 1 μM) |
|-----------------|-------------------------|-------------------|
| PMA10nM         |                         |                   |

5

Table 2

| treatment | F.U. at 535nm |      |           |
|-----------|---------------|------|-----------|
|           | Mean          | SD   | % control |
| Control   | 12043         | 173  | 100       |
| DMSO 0.1% | 11957         | 1131 | 99.2      |
| DMSO 1%   | 11584         | 1379 | 96.1      |
| DMSO 2%   | 11680         | 947  | 97        |
| DMSO 4%   | 12980         | 899  | 107.7     |
| DMSO 5%   | 13265         | 890  | 110.1     |

10

15

20

25

30

35

40

45

50

55

## SEQUENCE LISTING

5           <110> WARNER LAMBERT COMPANY  
10          <120> Methods and Compositions for Screening Icrcac Modulators  
15          <130> B0028EP  
20          <140>  
25          <141>  
30          <160> 2  
35          <170> PatentIn Ver. 2.1  
40          <210> 1  
45          <211> 30  
50          <212> DNA  
55          <213> Artificial Sequence  
60          <220>  
65          <223> Description of Artificial Sequence:  
70                 oligonucleotide  
75          <400> 1  
80          ggaggaaaaa ctgtttcata cagaaggcgt                 30  
85          <210> 2  
90          <211> 5  
95          <212> DNA  
100         <213> Artificial Sequence  
105         <220>  
110         <223> Description of Artificial Sequence:  
115                 oligonucleotide  
120          <400> 2  
125          cgtca                 5  
130

**Claims**

- 55     1. A method of screening a compound that modulates calcium channel activity, preferably calcium release-activated channel (Icrcac) activity, comprising:  
          a. contacting a test compound and a selective calcium channel activator, preferably an Icrcac activator with a

population of calcium channel expressing cells, preferably Icrcac expressing cells, said cells further containing a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter, and  
 b. determining the activity of the test compound on the calcium channel, preferably a calcium release-activated channel by measuring the reporter gene expression in said cells.

5

2. The method of claim 1, wherein, in step a), the cells are contacted with an Icrcac activator in the absence of a Protein Kinase C activator.

10

3. The method of claim 1 or 2, wherein the Icrcac activator is a product or a treatment that selectively depletes intracellular calcium stores, preferably thapsigargin.

4. The method of any one of claims 1-3, wherein the reporter gene is a  $\beta$ -lactamase gene.

15

5. The method of any one of the preceding claims, comprising

(a) contacting a test compound and a selective (direct or indirect) Icrcac activator with a population of Icrcac expressing cells, said cells further containing a reporter construct comprising a  $\beta$ -lactamase gene under the control of a NFAT-inducible promoter,

(b) contacting the cells of a) with a substrate of  $\beta$ -lactamase, and

(c) determining the activity of the test compound on the calcium release-activated channel by assessing the hydrolysis of the substrate in said cells.

6. The method of claim 5, wherein, in step b), the substrate is a ratiometric substrate.

25

7. The method of claim 6, wherein the substrate is CCF2-AM.

8. The method of any one of the preceding claims, wherein the population of cells comprises a culture of blood cells, particularly lymphocytes, mastocytes, or dendritic cells.

30

9. The method of any one of the preceding claims, wherein the test compound and Icrcac activator are contacted simultaneously with the cells.

10. The Method of any one of the preceding claims, wherein at least two test compounds are contacted in parallel with the cell population.

35

11. Method of claim 10 wherein at least 10, preferably at least 50 compounds are contacted in parallel.

12. Method of any one of the preceding claims, wherein step a) is performed in a multi-well plate.

40

13. Method according to anyone of the preceding claims, for screening compounds that inhibit the Icrcac activity.

14. Method of claim 13, wherein the cell population is incubated in a medium comprising at least 1 mM calcium.

15. Method according to anyone of claims 1 to 12, for screening compounds that stimulate the Icrcac activity.

45

16. A method according to anyone of claims 1 to 12, for characterizing or improving the activity of a test compound.

17. A method of screening for Icrcac blockers, comprising:

50

a. contacting a test compound and an Icrcac activator with a population of Icrcac-expressing cells, said cells further containing a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter, said cells being incubated in a medium containing at least 1 mM calcium and lacking phorbol ester,

b. contacting the cells of a) with a substrate of the reporter gene expression product, and

c. determining the activity of the test compound on the calcium release-activated channel by assessing the hydrolysis of the substrate in said cells.

55

18. A method of screening for Icrcac blockers, comprising:

- a. contacting a test compound and an Icrac activator with a population of Icrac-expressing cells, said cells further containing a reporter construct comprising a  $\beta$ -lactamase gene under the control of a NFAT-inducible promoter, said cells being incubated in a medium containing at least 1 mM calcium and lacking phorbol ester,  
5 b. contacting the cells of a) with a ratiometric substrate of  $\beta$ -lactamase, and  
c. determining the activity of the test compound on the calcium release-activated channel by assessing the hydrolysis of the substrate in said cells.

19. Method according to any one of claims 1 to 18, for screening a compound that modulates the activation of Icrac.

10 20. Method according to any one of claims 1 to 18, for screening a compound that modulates the Icrac-mediated calcium inflow.

21. Method according to any one of the preceding claims, further comprising d) the screening of the compounds obtained in c) in order to eliminate those which modulate  $\beta$ -lactamase activity in a non-NFAT dependent manner.

15 22. A kit for use in a method according to any of the preceding claims, comprising a cell population as defined in claim 1, a support, and a substrate.

20 23. A mastocyte or a mastocyte-derived cell, that contains a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter.

24. A population of rodent immune cells, in particular murine or rat immune cells, that comprises a reporter construct comprising a reporter gene under the control of a NFAT-inducible promoter.

25

30

35

40

45

50

55




Figure 1






Figure 2A

**Figure 2B****Figure 2C**







Figure 3



**Figure 4**



**Figure 5**

**Figure 6**




Figure 7



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 00 40 0923

| DOCUMENTS CONSIDERED TO BE RELEVANT  |  |                   | CLASSIFICATION OF THE APPLICATION (Int.Cl.)                    |
|--|--|-------------------|--|
| Category   | Citation of document with indication, where appropriate, of relevant passages  | Relevant to claim |  |
| A  | BRIDGLAND-TAYLOR MH ET AL: "Validation of a high throughput screen to detect potential modulators of Ca <sup>2+</sup> release-activated Ca <sup>2+</sup> channels in Jurkat T-cells"<br>BRITISH JOURNAL OF PHARMACOLOGY, vol. 125, no. PROC. SUPPL, December 1998 (1998-12), page 82p<br>XP000938347<br>see abstract<br>* the whole document * | 1,3,12,<br>20     | C12Q1/68<br>G01N33/50<br>//C12N5/10                            |
| A  | LOH C ET AL: "T-cell receptor stimulation elicits an early phase of activation and a later phase of deactivation of the transcription factor NFAT1"<br>MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 7, July 1996 (1996-07), pages 3945-54, XP000946105<br>* page 3946, paragraph 3 *   | 1                 |  |
| A  | FANGER C ET AL: "characterization of T cell mutants with defects in capacitative calcium entry: Genetic evidence for the physiological roles of CRAC channels"<br>JOURNAL OF CELL BIOLOGY, vol. 131, no. 3, November 1995 (1995-11), pages 655-67, XP000946096<br>see abstract   | 1,3               | TECHNICAL FIELDS<br>SEARCHED (Int.Cl.)<br>C12Q<br>C12N<br>G01N |
| A  | EP 0 982 398 A (UNIV CALIFORNIA)<br>1 March 2000 (2000-03-01)<br>* claims 1,8; example 13 *  | 1,4,5,<br>15-24   |  |
| A  | US 6 004 808 A (OFFERMANNS STEFAN ET AL)<br>21 December 1999 (1999-12-21)<br>* examples 6-8 *  | 1,4,5,<br>15-24   |  |
|  |  | -/-               |  |
| The present search report has been drawn up for all claims                       |  |                   |  |
| Place of search  | Date of completion of the search   | Examiner          |  |
| THE HAGUE  | 20 September 2000  | Osborne, H        |  |
| CATEGORY OF CITED DOCUMENTS  |  |                   |  |
| X : particularly relevant if taken alone   | T : theory or principle underlying the invention   |                   |  |
| Y : particularly relevant if combined with another document of the same category | E : earlier patent document, but published on, or after the filing date  |                   |  |
| A : technological background   | D : document cited in the application  |                   |  |
| O : non-written disclosure   | L : document cited for other reasons   |                   |  |
| P : intermediate document  | & : member of the same patent family, corresponding document   |                   |  |



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 00 40 0923

| DOCUMENTS CONSIDERED TO BE RELEVANT  |  |  | CLASSIFICATION OF THE APPLICATION (Int.Cl.) |                 |                                  |          |           |                   |            |
|--|--|--|---|-----------------|----------------------------------|----------|-----------|-------------------|------------|
| Category   | Citation of document with indication, where appropriate, of relevant passages  | Relevant to claim  |   |                 |                                  |          |           |                   |            |
| A  | WO 98 08979 A (UNIV CALIFORNIA)<br>5 March 1998 (1998-03-05)<br>* claim 13 *   | 1,13,15,<br>16,20  |   |                 |                                  |          |           |                   |            |
| T  | WO 00 40614 A (BETH ISRAEL HOSPITAL ; SCHARENBERG ANDREW M (US))<br>13 July 2000 (2000-07-13)<br>* page 44, line 16 - page 46, line 12;<br>claims 1,10,11,24 * | 1  |   |                 |                                  |          |           |                   |            |
|  |  |  | TECHNICAL FIELDS SEARCHED (Int.Cl.)         |                 |                                  |          |           |                   |            |
|  |  |  |   |                 |                                  |          |           |                   |            |
| <p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 33%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>20 September 2000</td> <td>Osborne, H</td> </tr> </table> |  |  |   | Place of search | Date of completion of the search | Examiner | THE HAGUE | 20 September 2000 | Osborne, H |
| Place of search  | Date of completion of the search   | Examiner   |   |                 |                                  |          |           |                   |            |
| THE HAGUE  | 20 September 2000  | Osborne, H   |   |                 |                                  |          |           |                   |            |
| CATEGORY OF CITED DOCUMENTS  |  | T : theory or principle underlying the invention<br>E : earlier patent document, but published on, or after the filing date<br>D : document cited in the application<br>L : document cited for other reasons<br>& : member of the same patent family, corresponding document |   |                 |                                  |          |           |                   |            |
| X : particularly relevant if taken alone<br>Y : particularly relevant if combined with another document of the same category<br>A : technological background<br>O : non-written disclosure<br>P : intermediate document  |  |  |   |                 |                                  |          |           |                   |            |

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 40 0923

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-09-2000

| Patent document cited in search report |   | Publication date | Patent family member(s)  | Publication date   |
|--|---|------------------|--|--|
| EP 0982398                             | A | 01-03-2000       | US 5741657 A<br>AU 723164 B<br>AU 5526696 A<br>CA 2215310 A<br>CN 1184479 A<br>EP 0817785 A<br>JP 11502714 T<br>WO 9630540 A | 21-04-1998<br>17-08-2000<br>16-10-1996<br>03-10-1996<br>10-06-1998<br>14-01-1998<br>09-03-1999<br>03-10-1996 |
| US 6004808                             | A | 21-12-1999       | AU 3572897 A<br>EP 1012324 A<br>WO 9748820 A   | 07-01-1998<br>28-06-2000<br>24-12-1997   |
| WO 9808979                             | A | 05-03-1998       | US 5932417 A<br>AU 4170597 A   | 03-08-1999<br>19-03-1998   |
| WO 0040614                             | A | 13-07-2000       | NONE   |  |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**